Neurodegenerative disorders present major challenges to global health, exacerbated by an aging population and the absence of therapies. Despite diverse pathological manifestations, they share a common hallmark, loosely termed ‘neuroinflammation’. The prevailing dogma is that the immune system is an active contributor to neurodegeneration; however, recent evidence challenges this. By analogy with road construction, which causes temporary closures and disruptions, the immune system's actions in the central nervous system (CNS) might initially appear destructive, and might even cause harm, while aiming to combat neurodegeneration. We propose that the application of cellular immunotherapies to coordinate the immune response towards remodeling might pave the way for new modes of tackling the roadblocks of neurodegenerative diseases.

Original languageEnglish
Pages (from-to)329-337
Number of pages9
JournalTrends in Immunology
Issue number5
StatePublished - May 2024


  • Alzheimer's disease
  • CAR-T therapy
  • immunotherapy
  • neurodegeneraive disorders
  • neuroimmunology


Dive into the research topics of 'Will cellular immunotherapies end neurodegenerative diseases?'. Together they form a unique fingerprint.

Cite this